文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

激活素A在早期识别中重度急性胰腺炎中的临床价值:一项前瞻性研究

[Clinical value of activin A in early identification of moderate and severe acute pancreatitis: a prospective study].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2022-01-01
一句话结论发病24小时内血清激活素A(ACT-A)>112.6 ng/L可早期识别中重度急性胰腺炎,特异性96.39%,优于CRP和Ranson评分。

该前瞻性病例对照研究纳入120例急性胰腺炎患者,按修订亚特兰大分类分为轻症组83例和中重度组37例,检测发病24小时内血清ACT-A和CRP水平,并计算Ranson评分和MCTSI。中重度组ACT-A、CRP、Ranson评分和MCTSI均显著高于轻症组(均P<0.01)。ACT-A与CRP、Ranson评分和MCTSI呈正相关(R²分别为0.272、0.841、0.616,均P<0.05)。ACT-A预测中重度AP的AUC为0.948,界值>112.6 ng/L时灵敏度和特异度分别为78.38%和96.39%,特异性优于Ranson评分(71.08%)。

要点

  • 中重度AP组发病24小时内血清ACT-A为140.4±37.7 ng/L,显著高于轻症组的53.9±30.5 ng/L(P<0.01)。
  • 血清ACT-A>112.6 ng/L预测中重度AP的灵敏度78.38%、特异度96.39%,AUC 0.948(95%CI 0.909-0.986)。
  • ACT-A预测中重度AP的特异性(96.39%)优于Ranson评分(71.08%),灵敏度优于CRP(72.92%)。
  • ACT-A与Ranson评分、MCTSI、CRP均呈正相关(R²分别为0.841、0.616、0.272,均P<0.05)。
  • 中重度AP组Ranson评分为5.3±1.3、MCTSI为5.5±1.0,均显著高于轻症组的1.8±1.6和2.7±1.2(均P<0.01)。

适用人群与场景

  • 2020年10月至2022年4月南华大学附属南华医院肝胆外科收治的120例急性胰腺炎患者,按修订亚特兰大分类分为轻症AP组83例和中重度AP组37例。

诊断标准与关键阈值

  • 采用修订亚特兰大分类将AP分为轻症AP和中重度AP。
  • 以血清ACT-A>112.6 ng/L作为预测中重度AP的界值,灵敏度78.38%、特异度96.39%。

研究设计与关键结果

  • 前瞻性病例对照研究,纳入120例AP患者(轻症83例、中重度37例),检测发病24小时内血清ACT-A和CRP,计算Ranson评分和MCTSI。
  • 中重度AP组发病24小时内ACT-A为140.4±37.7 ng/L vs 轻症组53.9±30.5 ng/L(P<0.01);lg CRP为1.42±0.91 vs 0.77±0.70(P<0.01)。
  • 中重度AP组Ranson评分为5.3±1.3 vs 轻症组1.8±1.6(P<0.01);MCTSI为5.5±1.0 vs 2.7±1.2(P<0.01)。
  • ACT-A与CRP、Ranson评分、MCTSI均呈正相关(R²=0.272、0.841、0.616,均P<0.05)。
  • ROC曲线分析:ACT-A预测中重度AP的AUC为0.948(95%CI 0.909-0.986),CRP为0.711(95%CI 0.606-0.815),Ranson评分为0.946(95%CI 0.910-0.982)。
  • ACT-A>112.6 ng/L预测中重度AP的灵敏度78.38%、特异度96.39%,优于CRP的灵敏度72.92%、特异度66.27%,特异性优于Ranson评分(71.08%)。

证据类型、等级与局限

  • 前瞻性病例对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为ACT-A可在AP早期检测,与疾病严重程度正相关,可早期识别中重度AP。
  • 对发病24小时内的AP患者,血清ACT-A>112.6 ng/L时中重度AP的可能性高(特异度96.39%),可辅助早期识别中重度AP。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the value of serum activin A (ACT-A) level in early identification of moderate and severe acute pancreatitis (AP).

METHODS: A prospective case control study was conducted. A total of 120 patients with AP admitted to department of hepatobiliary surgery of Affiliated Nanhua Hospital of Hengyang Medical College of University of South China between October 2020 and April 2022 were recruited. According to the revised Atlanta classification, all patients were classified into mild AP group and moderate-to-severe AP group. The blood samples within 24 hours of onset were drawn, and the serum ACT-A and C-reactive protein (CRP) levels were detected by enzyme-linked immunosorbent assay (ELISA). The Ranson score and the modified CT severity index (MCTSI) were performed. Pearson correlation method was used to analyze the correlation of various parameters. The receiver operator characteristic curve (ROC curve) was plotted to analyze the predictive value of ACT-A and CRP for moderate-to-severe AP.

RESULTS: A total of 120 patients with AP were enrolled, including 83 patients with mild AP and 37 patients with moderate-to-severe AP. Serum ACT-A and CRP levels within 24 hours of onset in the moderate-to-severe AP group were significantly higher than those in the mild AP group [ACT-A (ng/L): 140.4±37.7 vs. 53.9±30.5, lg CRP: 1.42±0.91 vs. 0.77±0.70, both P < 0.01], and the Ranson score and MCTSI score were also significantly higher than those in the mild AP group (Ranson score: 5.3±1.3 vs. 1.8±1.6, MCTSI score: 5.5±1.0 vs. 2.7±1.2, both P < 0.01). Correlation analysis showed that the serum ACT-A level was positively correlated with serum CRP level, Ranson score and MCTSI score (R2 value was 0.272, 0.841, 0.616, respectively, all P < 0.05). ROC curve analysis showed that the serum ACT-A, CRP and Ranson score had predictive value for moderate-to-severe AP. The area under the ROC curve (AUC) was 0.948 [95% confidence interval (95%CI) was 0.909-0.986], 0.711 (95%CI was 0.606-0.815), 0.946 (95%CI was 0.910-0.982), respectively. When serum ACT-A > 112.6 ng/L, the sensitivity and specificity of predicting moderate-to-severe AP were 78.38% and 96.39%, respectively, which was better than serum CRP with sensitivity and specificity of 72.92% and 66.27%, respectively, and the specificity was better than Ranson score (71.08%).

CONCLUSIONS: ACT-A can be detected in the early stage of AP, and it is positively correlated with the disease severity, which can early identify moderate-to-severe AP.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Liu X, Ma N, Long J, et al. [Clinical value of activin A in early identification of moderate and severe acute pancreatitis: a prospective study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36100412. doi:10.3760/cma.j.cn121430-20220523-00507

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。